Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07684313

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)

TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ascension St. Vincent's Hospital

Carmel, Indiana, 46260, United States

Location contact

David Heimansohn, MD

PRINCIPAL_INVESTIGATOR

About this study

Subjects in the TRIBLAZE study will be enrolled at up to 15 sites in the United States. The population will be participants requiring replacement of their native or prosthetic tricuspid valve.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older
  • Indication for TRIFORMIS valve implant for native or prosthetic valve dysfunction
  • Provide written informed consent prior to the 30-day imaging follow-up
  • Willing and able to return for scheduled follow-up visits

Exclusion criteria

  • Untreatable hypersensitivity to nitinol alloys (nickel and titanium)

Treatment and study plan

Edwards TRIFORMIS RESILIA heart valve

Device

Surgical replacement of the tricuspid valve with the Edwards TRIFORMIS RESILIA heart valve

Primary outcomes

  1. Participant's average mean gradient measurement over time

    Time frame: 1 Year

    Mean gradient is the average flow of blood through the tricuspid valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

  2. Participant's average peak gradient measurement over time

    Time frame: 1 Year

    Peak gradient is the maximum value measured of flow of blood through the tricuspid valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.

  3. Participant's average Effective Orifice Area (EOA) measurement over time

    Time frame: 1 Year

    Effective orifice area represents the cross-sectional area of the blood flow downstream of the tricuspid valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve.

  4. Participant's amount of tricuspid valvular regurgitation measurement over time

    Time frame: 1 Year

    Valvular regurgitation occurs when the valve in the heart does not close tightly, allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation, 1 = a trace of regurgitation, 2 = mild regurgitation, 3 = moderate regurgitation, and 4 represents severe regurgitation. Higher numbers on the scale show a worsening outcome.

  5. Participant's right ventricular function over time

    Time frame: 1 Year

    Right ventricular function is the heart's ability to pump deoxygenated blood through the pulmonary circulation into the lungs. Right ventricular function is assessed via echocardiography. It is assessed on a scale of: Normal, Mild dysfunction, Moderate dysfunction, Moderate-severe dysfunction, or Severe dysfunction.

  6. Participant's amount of paravalvular leak over time

    Time frame: 1 Year

    Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.

  7. Participant's quality of life improvement as measured on the Kansas City Cardiomyopathy Questionnaire from baseline to 1 year

    Time frame: Baseline and 1 Year

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated, disease-specific health status tool for patients with heart failure. It measures symptoms, physical and social limitations, and quality of life over the previous two weeks. Scores range from 0 to 100, where higher numbers indicate better health and fewer symptoms and lower numbers indicate wore health and more symptoms.

Secondary outcomes

  1. Participant's functional improvement over time from baseline for New York Heart Association (NYHA) Class

    Time frame: Baseline, 1 month, 1-, 2-, 3-, 4-, and 5- Years follow-up

    The New York Heart Association functional classification system relates symptoms to everyday activities and the patient's quality of life.

    Class I. Patients with cardiac disease but without resulting limitation of physical activity.

    Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.

    Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.

    Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.

    Symptoms of heart failure or anginal syndrome may be present even at rest.

  2. Percentage of participant's freedom from all cause mortality

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from all cause mortality. Time to events were estimated by Kaplan-Meier method.

  3. Percentage of participant's freedom from cardiovascular mortality

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from cardiovascular mortality. Time to events were estimated by Kaplan-Meier method.

  4. Percentage of participant's freedom from valve-related mortality

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from valve-related mortality. Time to events were estimated by Kaplan-Meier method.

  5. Percentage of participant's freedom from tricuspid valve reintervention

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from a reoperation on their tricuspid valve. Time to events were estimated by Kaplan-Meier method.

  6. Percentage of participant's freedom from valve-related pulmonary embolism

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from valve-related pulmonary embolism. Time to events were estimated by Kaplan-Meier method.

  7. Percentage of participant's freedom from valve-related valve thrombosis

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from valve-related valve thrombosis. Time to events were estimated by Kaplan-Meier method.

  8. Percentage of participant's freedom from valve-related hemorrhage

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from valve-related hemorrhage. Time to events were estimated by Kaplan-Meier method.

  9. Percentage of participant's freedom from valve-related endocarditis

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from valve-related endocarditis. Time to events were estimated by Kaplan-Meier method.

  10. Percentage of participant's freedom from tricuspid valve-related heart failure hospitalization

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

    Participants' freedom from tricuspid valve-related heart failure hospitalization. Time to events were estimated by Kaplan-Meier method.

Study contacts

Contact information is provided by the study sponsor or research team.

Aya Westbrook, PhD

CONTACT

[email protected]

949-250-2500

Sponsors and collaborators

Lead sponsor

Edwards Lifesciences

Industry

Registry information

Official study title

Multi-center, Single-arm, Observational Study Assessing Real-world Safety and Performance of the TRIFORMIS RESILIA Tricuspid Valve for Surgical Tricuspid Valve Replacement (TRIBLAZE Study)

Acronym: TRIBLAZE

Important dates

Study start
2026
Primary completion
2030
Study completion
2034
First posted
Jul 6, 2026
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.